Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With No Approved Meds

Biohaven’s troriluzole, which initially failed a pivotal study in spinocerebellar ataxia, is now being readied for an FDA submission in this rare neurodegenerative disease. The turnabout is based on positive results from a new study that incorporated real-world evidence. The post Real-World Data Salvage Biohaven Drug, Paving Way for FDA Filing in Neuro Disease With…

Read More

Oct. 1 Virtual Event: What the 2024 Election Could Mean for Health Coverage, Affordability, and the Budget

As the 2024 presidential election draws near, there are sharp differences in former President Trump’s and Vice President Harris’ records on health coverage and spending, including the Affordable Care Act, Medicaid, prescription drugs, and more. At Noon ET on Tuesday, October 1, Larry Levitt, KFF’s executive vice president for health policy, will moderate a 45-minute…More

Read More

Navigating Economic Uncertainty in Biopharma

The biopharmaceutical industry clearly isn’t going anywhere, but we’ve been in a downward business cycle. We’ve learned a lot from the pandemic and have adopted novel approaches to development and this current economic challenge will also inform us. In the meantime, adopting these strategies can de-risk your development programs. The post Navigating Economic Uncertainty in…

Read More

The Public Health Consequences of Public Housing Failures

Every year more than 10,000 taxpayer-supported public housing units are lost to disrepair. But federal lawmakers routinely ignore the full amount, around $115 billion, needed to keep the units in “decent, safe and sanitary” condition. One-time funds for public housing repairs were cut from the final version of the 2022 Inflation Reduction Act to appeal…

Read More